179 related articles for article (PubMed ID: 33749792)
1. Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus.
Kralova E; Marusakova M; Hadova K; Krenek P; Klimas J
J Pharm Pharmacol; 2021 Apr; 73(6):778-784. PubMed ID: 33749792
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
Liu L; Luo H; Liang Y; Tang J; Shu Y
Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
Belosludtsev KN; Starinets VS; Belosludtsev MN; Mikheeva IB; Dubinin MV; Belosludtseva NV
Mitochondrion; 2021 Jul; 59():246-254. PubMed ID: 34144205
[TBL] [Abstract][Full Text] [Related]
5. Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes.
Skovsø S; Damgaard J; Fels JJ; Olsen GS; Wolf XA; Rolin B; Holst JJ
Int J Obes (Lond); 2015 Oct; 39(10):1531-8. PubMed ID: 26121961
[TBL] [Abstract][Full Text] [Related]
6. Reduced
Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.
Hamouda NN; Sydorenko V; Qureshi MA; Alkaabi JM; Oz M; Howarth FC
Mol Cell Biochem; 2015 Feb; 400(1-2):57-68. PubMed ID: 25351341
[TBL] [Abstract][Full Text] [Related]
8. Insulin dependent and independent normalization of blood glucose levels reduces the enhanced rewarding effects of nicotine in a rodent model of diabetes.
Íbias J; O'Dell LE; Nazarian A
Behav Brain Res; 2018 Oct; 351():75-82. PubMed ID: 29803655
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Tanday N; Irwin N; Flatt PR; Moffett RC
Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
[TBL] [Abstract][Full Text] [Related]
10. Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Fleifel AM; Soubh AA; Abdallah DM; Ahmed KA; El-Abhar HS
Life Sci; 2022 Oct; 307():120865. PubMed ID: 35934057
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
[TBL] [Abstract][Full Text] [Related]
12. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
Hodrea J; Saeed A; Molnar A; Fintha A; Barczi A; Wagner LJ; Szabo AJ; Fekete A; Balogh DB
PLoS One; 2022; 17(2):e0263285. PubMed ID: 35176041
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
[TBL] [Abstract][Full Text] [Related]
16. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
17. Chlorogenic acid inhibits forming of diabetes mellitus in rats induced by high-fat high-sucrose and streptozotocin.
Wang Y; Peng S; Mei Z; Jin C; Kang J; Xiang M; Wang Z; Hu Y
Pak J Pharm Sci; 2020 May; 33(3):1063-1072. PubMed ID: 33191230
[TBL] [Abstract][Full Text] [Related]
18. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
Guo Z; Qin Z; Zhang R; Li J; Yin Y
Eur J Pharmacol; 2012 Jun; 685(1-3):116-25. PubMed ID: 22542658
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
